Product information and disease descriptionPlace of product in therapyApproaches to treatment
Place in treatment, anticipated use, and care setting
1 evidence topic · 4 sources
Summary
The proposed U.S. indication is smoking cessation in adults. Development studied oral cytisinicline with behavioral support. WHO includes cytisine among recommended tobacco-cessation pharmacotherapies and recommends combining medication with behavioral interventions. U.S. commercial use remains contingent on FDA approval; the sponsor anticipated potential approval in the first half of 2027.